Recent News

• 10.02.2025 - PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society
• 10.02.2025 - PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society
• 09.26.2025 - PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
• 09.26.2025 - PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
• 09.25.2025 - PepGen Announces Pricing of $100 Million Public Offering
• 09.25.2025 - PepGen Announces Pricing of $100 Million Public Offering
• 09.24.2025 - PepGen Announces Proposed Public Offering
• 09.24.2025 - PepGen Announces Proposed Public Offering
• 09.24.2025 - PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients
• 09.24.2025 - PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients

Recent Filings

• 09.30.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 09.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.26.2025 - EX-99.1 EX-99.1
• 09.26.2025 - 8-K Current report
• 09.25.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 09.24.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 09.24.2025 - 8-K Current report
• 09.24.2025 - EX-99.1 EX-99.1
• 08.13.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors